Penn Capital Management Company LLC Sells 21,128 Shares of RadNet, Inc. $RDNT

Penn Capital Management Company LLC cut its stake in RadNet, Inc. (NASDAQ:RDNT) by 7.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 250,224 shares of the medical research company’s stock after selling 21,128 shares during the period. RadNet accounts for approximately 1.3% of Penn Capital Management Company LLC’s portfolio, making the stock its 29th largest position. Penn Capital Management Company LLC’s holdings in RadNet were worth $17,282,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of RDNT. Farther Finance Advisors LLC grew its holdings in shares of RadNet by 60.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 596 shares of the medical research company’s stock worth $41,000 after acquiring an additional 224 shares during the period. Parallel Advisors LLC raised its position in shares of RadNet by 80.0% in the 1st quarter. Parallel Advisors LLC now owns 1,114 shares of the medical research company’s stock worth $62,000 after acquiring an additional 495 shares in the last quarter. Nykredit A S bought a new position in shares of RadNet in the 2nd quarter worth approximately $153,000. GAMMA Investing LLC raised its position in shares of RadNet by 10.6% in the 3rd quarter. GAMMA Investing LLC now owns 2,321 shares of the medical research company’s stock worth $160,000 after acquiring an additional 222 shares in the last quarter. Finally, Modera Wealth Management LLC purchased a new position in shares of RadNet in the 3rd quarter valued at approximately $207,000. 77.90% of the stock is owned by institutional investors.

RadNet Price Performance

Shares of NASDAQ:RDNT opened at $78.38 on Tuesday. The business has a fifty day moving average price of $72.64 and a 200-day moving average price of $65.43. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.48 and a quick ratio of 1.48. The company has a market capitalization of $6.17 billion, a PE ratio of 182.41 and a beta of 1.42. RadNet, Inc. has a 1-year low of $50.82 and a 1-year high of $85.84.

RadNet (NASDAQ:RDNT) last announced its quarterly earnings results on Sunday, November 8th. The medical research company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.08. The company had revenue of $638.26 million for the quarter, compared to analysts’ expectations of $639.97 million. RadNet had a negative net margin of 0.93% and a positive return on equity of 2.61%. RadNet’s revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.20 EPS. As a group, equities analysts expect that RadNet, Inc. will post 0.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on RDNT. Zacks Research upgraded RadNet from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 9th. Truist Financial increased their price objective on RadNet from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Raymond James Financial reissued a “strong-buy” rating on shares of RadNet in a research report on Tuesday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of RadNet in a report on Wednesday, November 4th. Finally, Barclays boosted their target price on shares of RadNet from $65.00 to $79.00 and gave the company an “overweight” rating in a report on Friday, August 28th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $90.00.

Key RadNet News

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: RadNet reported Q3 EPS of $0.30, beating the $0.22 consensus estimate by 35%. Revenue rose 22.1% year over year to $638.26 million, while the company also reported record quarterly revenue and adjusted EBITDA. RadNet Q3 financial results and revised guidance
• Positive Sentiment: The company raised its 2026 revenue guidance to $2.5 billion–$2.6 billion, versus analyst expectations of about $2.5 billion. This marked its third consecutive quarterly guidance increase. RadNet Q3 earnings and guidance
• Negative Sentiment: Revenue of $638.26 million narrowly missed the $639.97 million consensus estimate, tempering an otherwise strong quarter. RadNet earnings report

About RadNet

RadNet, Inc operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging.

The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.

RadNet also develops digital health and artificial intelligence solutions through its subsidiary DeepHealth, including technology intended to support imaging workflows and assist with image analysis.